Key result
ICU admission is linked to ~7.6-fold higher mortality among LVAD patients with COVID-19.
Why the study?
Patients on LVAD support may be susceptible to severe disease and complications from COVID-19, prompting this study to describe the clinical course of COVID-19 in LVAD patients.
Cohort (n=34)
No
COVID-19 infection carries a high risk of morbidity and mortality in patients on LVAD support, as well as a high rate of postoperative stroke and complicated recovery in patients with prior COVID-19 undergoing de novo LVAD implantation.
Answers are grounded in this paper and cite their sources.
Supports close monitoring for respiratory failure in LVAD patients with COVID-19; leaves open whether preventive strategies reduce mortality.
Patients on left ventricular assist device (LVAD) support may be susceptible to severe disease and complications from coronavirus disease-19 (COVID-19). The purpose of this study was to describe the clinical course of COVID-19 in LVAD patients. A retrospective review was performed at our center; 28 LVAD patients who developed COVID-19 between March 2020 and March 2021, and six patients with a prior COVID-19 infection who underwent LVAD implantation, were identified and examined. Of the 28 patients, nine (32%) died during the study period, five (18%) during their index hospitalization for COVID-19. Two patients (7%) presented with suspected pump thrombosis. In a nonadjusted binary regression logistic analysis, admission to the intensive care unit (unadjusted odds ratio, 7.6 [CI, 1.2-48], P = 0.03), and the need for mechanical ventilation (unadjusted odds ratio 14 [CI, 1.3-159], P = 0.03) were associated with mortality. The six patients who previously had COVID-19 and subsequently received a LVAD were on intra-aortic balloon pump and inotropic support at time of surgery. All six experienced a complicated and prolonged postoperative course. Three patients (50%) suffered from ischemic stroke, and there was one (17%) 30 day mortality. We observed an increased risk of morbidity and mortality in LVAD patients with COVID-19.
No takes yet. Share an insight, caveat, or question.
Zakrzewski et al. (2021) conducted a cohort in Left ventricular assist device (LVAD) support with COVID-19 infection (n=34). COVID-19 infection in LVAD patients was evaluated on Mortality during the study period (OR 7.6, 95% CI 1.2-48, p=0.03).
Synapse has enriched 10 related papers. Consider them for comparative context: